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I am in agreementwithDrsKorst and
Lee that there may be certain popula-
tions with nondysplastic Barrett’s
esophagus (BE) who may be at in-
creased risk for esophageal cancer.
There are currently no compelling
data, however, to recommend any inter-
vention beyond repeated surveillance
endoscopy in patients with BE. The
American Gastroenterological Associ-
ation based its recommendation for
surveillance on an estimated rate of
progression of disease to high-grade
dysplasia or adenocarcinoma of 0.5%.
Recent large, population-based studies
suggest that this risk estimate is actu-
ally too high. Hvid-Jensen and colle-
ages1 reported in the New England
Journal of Medicine in October 2011
an annual risk of progression to adeno-
carcinoma in patients with BE of
0.12%. This findingwas based on anal-
ysis of a comprehensive database that
included the entire population of Den-
mark. In a similar study of the entire
population of Northern Ireland, Bhat
and colleagues2 reported a nearly iden-
tical absolute annual risk of 0.13%.
Current data indicate that the risk to
the patient of malignant transformation
from BE is even lower than previously
thought, suggesting caution with inva-
sive strategies that may in fact be over-
treatment. There may be a role for
radiofrequency ablation in selected—
and currently undefined—subgroups
of patients with nondysplastic BE.The JournalGiven the overall low cancer risk, the
bar is set very high to prove cost-
effectiveness, reduction in cancer pro-
gression, or reduction in mortality.
I believe that radiofrequency ablation
for nondysplastic BE is therefore diffi-
cult to justify, outside of a well-
reasoned clinical trial.
Nirmal K. Veeramachaneni, MD
Division of Cardiothoracic Surgery
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FAILURE: DOWE NEED A NEW
CONFIGURATION?
To the Editor:
We read with great interest the arti-
cle by Bonacchi and colleagues1 in
a recent issue of The Journal of Tho-
racic and Cardiovascular Surgery.
Bonacchi and colleagues1 presented
their experience with the use of veno-
venous extracorporeal membrane ox-
ygenation (ECMO) in 30 patients
with severe acute respiratory failure
and described their experience with
the use of a customized arterial can-
nula to reduce the blood recirculation
fraction (BRF) when high ECMO
flows are needed to improve systemic
oxygenation. In their ‘‘c’’ configura-
tion, a traditional inflow cannula is
modified by making a 60 angle in
its distal third to allow tip orientation
toward the tricuspid valve. In their se-
ries, Bonacchi and colleagues1 re-
ported significant improvements inof Thoracic and Cardiovascular Surgeoxygenation indices and a reduction
of more than 20% in the BRF. Impor-
tantly, the study showed that the mod-
ified cannula can be used safely
without mechanical complications.
The problem of recirculation with
a double-lumen catheter for venove-
nous ECMO has been well studied
in both animal and human models.2-4
In patients with acute respiratory
failure who require high ECMO
flow support, a low BRF is key to
ensure adequate systemic oxygen
delivery. The study by Bonacchi and
colleagues1 addresses this important
issue and demonstrates that a low
BRF is associated with successful ve-
novenous ECMO in patients with re-
spiratory distress. Although we
recognize the efforts of Bonacchi
and colleagues1 to develop a new
strategy to overcome the problem of
BRF when high ECMO flows are
needed, we would like to point out
several important points that they
failed to include in their report. First,
a bicaval dual-lumen catheter that is
already available in the United States
(Avalon Elite; Avalon Laboratories
LLC, Rancho Dominguez, Calif)
can be safely and successfully used
to provide adequate venovenous
ECMO support in patients with acute
respiratory failure.5 Second, the use
of this dual-lumen Avalon Elite can-
nula offers the advantage of single-
site cannulation, eliminates the need
to use multiple catheters, and avoids
the use femoral vascular access.5
Third, studies have shown that the
use of the dual-lumen Avalon Elite
cannula results in a very small BRF
(as low as 2%).6 Finally, placement
of the dual-lumen Avalon Elite can-
nula can be successfully achieved
with fluoroscopic and a transthoracic
echocardiographic guidance and does
not require an invasive transesopha-
geal approach.7
Although we applaud the efforts of
Bonacchi and colleagues1 and recog-
nize the value of their technique in
overcoming the problem of BRF, we
believe that the use of the currentlyry c Volume 143, Number 4 993
Letters to the Editoravailable dual-lumen Avalon Elite
cannula offers many advantages rela-
tive to their proposed new configura-
tion and should be the preferred
approach for patients with acute respi-
ratory failure and for those being
bridged to lung transplant. The use
of the modified catheter and c config-
uration of Bonacchi and colleagues1
should be limited to patients who
have no access to the currently avail-
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Regarding the role ofc configuration
at the dawning of adult bi-lumen can-
nula era for venovenous extracorporeal
membrane oxygenation (ECMO), we
read with interest the letter of Diaz-
Guzman and colleagues from the Uni-
versity of Kentucky Transplant Center
concerning our novel strategy for
blood-oxygenation optimization in
venovenous extracorporeal ECMO,
which we call the ‘‘c configuration.’’
We appreciate all the useful comments
received in response to the publication
of our article.1
The c configuration strategy was
born in early 2007, which was 2 years
before the adult bicaval dual-lumen
catheter (Avalon Elite; Avalon Labora-
tories, LLC, Rancho Dominguez, Ca-
lif) became clinically available (since
January15, 2009, inEurope).2The con-
figuration was introduced to respond to
some difficulties in adequate blood ox-
ygenation with venovenous ECMO:
achieving optimal oxygenation in all
patients with severely impaired pulmo-
nary functions (when high ECMO
flows are needed to improve systemic
oxygenation during protective ventila-
tion to improve pulmonary recovery)
and reducing the blood recirculation
fraction to ensure adequate systemic
oxygen delivery. The strategy was
applied with a standard but custom-
ized cannula, and placement was
successfully achieved with transtho-
racic or transesophageal echocardio-
graphic guidance.
Since February 2009, we have used
Avalon bilumen cannulas (to our
knowledge, we are the first center in
Europe and among the first in the
world to do so). To date, we have
treated more than 25 patients, with
an ongoing research protocol to com-
pare Avalon and c configurationardiovascular Surgery c April 2012performance. Indeed, the theoretic
and physiologic concepts of the Ava-
lon cannula and c configuration basis
are the same: to drain venous blood
from both venae cavae and to reinfuse
oxygenated blood directly thought the
tricuspid valve to reduce the blood re-
circulation fraction and to optimize
blood oxygenation.
Furthermore, from our initial experi-
ence, the bilumen cannula presents var-
ious advantages that are correctly
reported by Diaz-Guzman and col-
leagues; nevertheless, its limits and dis-
advantages were not presented.
Intrinsically, the adult bilumen cannula
presents some structural limitations and
clinical restrictions.3-5 In contrast with
Diaz-Guzman and colleagues, we think
that an adequate and strict patient selec-
tion is necessary for appropriate use of
this device to achieve optimal results.
From our initial experience we have
identified some principal limitations of
the adult Avalon bilumen cannula:
Maximalbloodflowachieved:Also
with a major dimension cannula (31 F)
the limit in bloodflow is 5 to 6L/min.3-5
This value could be inadequate in
different clinical scenarios, such as
when pulmonary function is very
impaired and patients require deep
protective pulmonary ventilation.1 In
this situation, the complete extracorpo-
real blood oxygenation is necessary
(venovenous ECMO blood flow
>75% of cardiac output1). The data in
our hands seem to indicate that in these
circumstances the flow generated from
a 31F cannula could be insufficient, if
a patient’s body surface area is greater
than 2.0 m2 or body weight is greater
than 80 kg (with our configuration, we
have treated with no problems obese
patients up to a body weight of 165
kg), especially if protective pulmonary
ventilation is required. Similar consid-
erations could be applied to smaller pa-
tients with hyperdynamic status (such
as septic shock or fever). We have
treated patients with cardiac outputs as
great as 22 L/min.
Inflow and outflowpressure gradi-
ent:Fromour data (as yet unpublished)
